PHVS Pharvaris N.V.
Price Chart
Executive Summary
Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Phase 3 RAPIDe-3 on-demand HAE data and Phase 2 CHAPTER-1 OLE prophylaxis data. The event is a routine scientific conference update with no new clinical data released today; the key catalyst remains the CHAPTER-3 topline data expected in Q3 2026.
Actionable Insight
This is a routine conference update with no new data released. The next major catalyst is CHAPTER-3 topline data in Q3 2026. Monitor EAACI presentations for any incremental safety/efficacy signals, but no immediate trading action warranted.
Key Facts
- 8 abstracts accepted at EAACI 2026 (June 12-15, Istanbul), including 1 oral presentation of RAPIDe-3 Phase 3 on-demand HAE data
- 7 additional presentations cover cardiovascular safety, biomarker assay, RAPIDe-3 patient voices, and CHAPTER-1 OLE prophylaxis results
- CHAPTER-3 global pivotal Phase 3 study of deucrictibant XR for HAE prophylaxis ongoing; topline data expected Q3 2026
- CREAATE Phase 3 study for AAE-C1INH (prophylactic and on-demand) also ongoing
- No new clinical data or regulatory milestones announced in this press release
Financial Impact
No financial data disclosed; event is a scientific conference update with no revenue or cost implications
Risk Factors
- No new clinical data released today; market may be disappointed by lack of material update
- CHAPTER-3 topline data in Q3 2026 is binary risk for the stock
- Competitive landscape includes existing injectable HAE therapies (Takhzyro, Firazyr) and oral competitors (Orladeyo)
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303489 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
11d ago
|
Press Release
| $30.16 $31.09 | ▲ +3.08% | ▲ +5.61% | $31.59 (+4.74%) |
|
May 26, 2026
14d ago
|
Insider Cluster
| $29.47 $30.14 | ▲ +2.27% | ▲ +1.80% | $31.59 (+7.19%) |
|
May 26, 2026
14d ago
|
Insider Cluster
| $29.47 $30.14 | ▼ −2.27% | ▼ −1.80% | $31.59 (−7.19%) |
|
May 22, 2026
18d ago
|
Insider Cluster
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.63% | $31.59 (+6.44%) |
|
May 21, 2026
19d ago
|
144
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.61% | $31.59 (+6.44%) |
|
May 20, 2026
20d ago
|
Insider Cluster
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $31.59 (+3.44%) |
|
May 20, 2026
20d ago
|
144
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $31.59 (+3.44%) |
|
May 19, 2026
21d ago
|
Insider Cluster
| $29.45 $29.86 | ▲ +1.39% | ▼ −0.41% | $31.59 (+7.27%) |
|
May 12, 2026
28d ago
|
Press Release
| $32.94 $28.95 | ▼ −12.11% | ▼ −10.95% | $31.59 (−4.10%) |
|
May 11, 2026
29d ago
|
6-K
| $31.25 $28.81 | ▼ −7.81% | ▼ −7.89% | $31.59 (+1.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access